Daghistani, Mustafa <br/><br/>
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.  [electronic resource] 

 -  Blood  Dec 2010 
 - 6014-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2010-01-264234  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzamides<br/>Blast Crisis<br/>DNA-Binding Proteins--genetics<br/>Dasatinib<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Humans<br/>Imatinib Mesylate<br/>In Situ Hybridization, Fluorescence<br/>Leukemia, Myeloid, Chronic-Phase--drug therapy<br/>MDS1 and EVI1 Complex Locus Protein<br/>Male<br/>Middle Aged<br/>Piperazines--therapeutic use<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogenes--genetics<br/>Pyrimidines--therapeutic use<br/>RNA, Messenger--genetics<br/>RNA, Neoplasm--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Salvage Therapy<br/>Survival Rate<br/>Thiazoles--therapeutic use<br/>Transcription Factors--genetics